Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia
- 30 June 2008
- journal article
- research article
- Published by Elsevier BV in Journal of Infection
- Vol. 56 (6), 432-436
- https://doi.org/10.1016/j.jinf.2008.04.002
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumanniiScandinavian Journal of Infectious Diseases, 2007
- Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICUInternational Journal of Antimicrobial Agents, 2006
- Parenteral and Inhaled Colistin for Treatment of Ventilator-Associated PneumoniaClinical Infectious Diseases, 2006
- Treatment options for multidrug-resistant bacteriaExpert Review of Anti-infective Therapy, 2006
- Ventilator-associated pneumoniaCurrent Opinion in Pulmonary Medicine, 2005
- Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial InfectionsClinical Infectious Diseases, 2005
- Evaluation of colistin as an agent against multi-resistant Gram-negative bacteriaInternational Journal of Antimicrobial Agents, 2005
- Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to CliniciansAnnals of Pharmacotherapy, 2004
- Risk Factors forAcinetobacter baumanniiNosocomial Bacteremia in Critically Ill Patients: A Cohort StudyClinical Infectious Diseases, 2001
- Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumanniiJournal of Antimicrobial Chemotherapy, 1998